Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 205

Results For "improve"

2629 News Found

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical
Biotech | May 02, 2022

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical

Avacc 3 has significant advantages over existing whooping cough vaccines


USFDA concludes inspection of Shilpa Medicare with four observations
News | May 02, 2022

USFDA concludes inspection of Shilpa Medicare with four observations

The inspection was triggered by Shilpa's submission of applications for four ANDA's to seek approval to use this site as an alternate testing laboratory


Physicians foresee an Alzheimer's Disease treatment revolution supported by advanced testing tools
Biotech | May 02, 2022

Physicians foresee an Alzheimer's Disease treatment revolution supported by advanced testing tools

Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education


Global Cord Blood Corp acquires Cellenkos to advance cell therapy market
Biotech | May 01, 2022

Global Cord Blood Corp acquires Cellenkos to advance cell therapy market

CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products


ASPIRE 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis
Public Health | May 01, 2022

ASPIRE 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis

It affects up to 10 per cent of women of reproductive age around the world


Ultomiris approved in the US for adults with generalised myasthenia gravis
Drug Approval | April 29, 2022

Ultomiris approved in the US for adults with generalised myasthenia gravis

Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks


Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec
Biotech | April 29, 2022

Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec

In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec


Philips and Prisma Health sign multi-year, long-term strategic partnership
Digitisation | April 29, 2022

Philips and Prisma Health sign multi-year, long-term strategic partnership

South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim


Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Biotech | April 29, 2022

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo


AstraZeneca expands its ‘Young Health Program’ in Delhi
Public Health | April 29, 2022

AstraZeneca expands its ‘Young Health Program’ in Delhi

For over a decade, AstraZeneca and Plan India’s Young Health Program have been generating awareness and identifying sustainable solutions to influence the behaviour of youths against Non-Communicable Diseases